Review highlights the role of histone deacetylases and their inhibitors in neurodegenerative diseases, suggesting astrocytes as promising therapeutic targets.
Key Points
HDAC inhibitors can improve cognitive and motor functions in neurodegenerative diseases, enhancing therapeutic potential.
Preclinical and clinical studies indicate that HDACi reduce neuroinflammatory markers and mitigate neurodegeneration effectively.
Targeting astrocytes with HDAC inhibitors may promote a neuroprotective environment, complementing neuron-focused therapies.
Emerging evidence emphasizes the need for multi-target drugs and new therapeutic strategies in managing neurodegenerative diseases.